Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-7190

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-7190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A geometric mean ratio chart with 90% confidence intervals showing pharmacokinetic changes (Cmax and AUC) of desvenlafaxine extended release tablets in various populations, including renal impairment (mild to ESRD), hepatic impairment (mild to severe), and demographics such as gender and age groups (65-75 years, >75 years). The chart presents changes relative to reference values.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A forest plot showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for desvenlafaxine when coadministered with the CYP3A4 inhibitor ketoconazole. The x-axis represents the change relative to reference from 0.50 to 2.0, with points for Cmax near 1.08 and AUC near 1.43.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A chart depicting geometric mean ratios and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC) of various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) when co-administered with Desvenlafaxine. The x-axis shows change relative to reference, ranging from 0.5 to 2.5, indicating pharmacokinetic interactions with CYP2D6 and CYP3A4 enzyme substrates.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A Kaplan-Meier curve comparing the estimated proportion of patients with relapse over time (up to 200 days) between Desvenlafaxine 50 mg and placebo groups. The x-axis represents time to relapse in days from randomization, and the y-axis shows the estimated proportion of patients with relapse as a percentage. The Desvenlafaxine group curve consistently remains below the placebo curve, indicating a lower relapse rate over time with Desvenlafaxine treatment.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A line graph showing the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine and placebo. The graph plots time on the x-axis (0 to 200 days) and estimated relapse proportion on the y-axis (0% to 50%). The Desvenlafaxine group is represented by a solid blue line, showing a lower relapse rate over time compared to the placebo group, represented by a dashed red line.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure of desvenlafaxine showing the molecular arrangement including a phenol group, a cyclohexanol ring, a dimethylaminoethyl side chain, two carboxylic acid groups, and a water molecule representing its hydrate form.*

FDA Label Image

Label Image (Lbl500907190)

DESVENLAFAXINE 25 mg extended-release oral tablets label from A-S Medication Solutions. The label indicates the active ingredient dosage, storage instructions (store at 68 to 77 degrees Fahrenheit), package quantity (30 tablets), and directions to see package insert. The NDC is 50090-7190.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.